Summit Therapeutics Share Discussion Threads

[chrisatrdg] 26/4/2018 16:13

Currently the NASDAQ is again ahead of AIM & currently is at $14.05 = £2.02 not sure why AIM has not followed.As said earlier if sustained on NASDAQ maybe AIM will follow.

Edit: Final close $13.82 = £1.99.

[luminoso] 26/4/2018 15:53

Tomorrow, when/if its clear the nasdaq rise will hold for the rest of today.

[football] 26/4/2018 15:18

when is this going blue over here?

[waterloo01] 26/4/2018 10:33

3rd Q so by end September.

[football] 26/4/2018 09:35

When roughly will you be looking at seeing the results of the 48 week trials or is it still a good few months off?

[waterloo01] 24/4/2018 20:03

Good to see us up on a bad day on Nasdaq.

Summit Therapeutics presents highly encouraging data in DMD
Company: Summit Therapeutics (SMMT)

Therapy: Ezutromid

Disease: Duchenne muscular dystrophy (DMD)

News: SMMT delivered a presentation of a 24-week analysis of its phase 2, open-label PhaseOut DMD study, which is assessing its utrophin modulator ezutromid in patients with DMD. The findings were presented at the 70th American Academy of Neurology Annual Meeting. In the 40 patients treated with ezutromid, there was a 2.61% reduction in the muscle fibers expressing MHCd, while utrophin intensity was increased by a mean of 0.026%, the former a measure of muscle damage. Together, these findings provide evidence that ezutromid treatment is addressing the underlying pathology of DMD to improve muscle activity.

Looking forward: This continues a saga of interesting development for SMMT, as ezutromid is the first agent acting as a utrophin modulator, and although the study was not specifically designed to assess changes in these biopsy-led tests, it provides a favorable indication of resolution of underlying disease biology. SMMT anticipates a 48-week readout to come in Q3 2018. And while I wouldn't get my hopes up too high on this one, these data do nothing but encourage.

Very interesting findings, but this is still early enough to present an imbalanced risk/benefit for me.

[football] 24/4/2018 14:54

Looks like we have a seller over the side of the pond but off to a good start state side

[hugus maximus] 24/4/2018 13:34

I wonder if a potential date of significance re: Summit relationship with Sarepta could be May 3rd when Sarepta publish Y/E figures and announce corporate direction?

[fig1] 23/4/2018 20:21

https://dailym.ai/2FagsWQ

[luminoso] 23/4/2018 17:41

Sarepta also down. Could be biotech stocks seen as a risk to offload by some, because US treasuries approaching the psychological 3% yield mark that seems to have the talking heads spooked in US.
Or they don’t like the options rns much.
Only my musings.

[chrisatrdg] 23/4/2018 12:15

2 RNS's out incl ECCMID presentation:



Discovery of a Novel Oral Antibiotic, to Treat Multi-Drug Resistant Neisseria gonorrhoeae Enabled by a Proprietary Transposon Technology - see below:



Edit:
Hi All - Good to see the second RNS relating to Summits new Discuva platform just need someone to explain it all but also good that there will be a further update H2 2018.Onwards & upwards.We may get a more positive reaction on the NASDAQ.

[hugus maximus] 21/4/2018 16:49

Waterloo refers to .. the National Institute of Arthritis and Musculoskeletal and Skin Diseases research(Based in Maryland) must be something the FDA have seen. It's absolutely categorical that qMR (MRI) is a better means of finding an end point than 6MWT:
hxxp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194283

[waterloo01] 21/4/2018 13:33

I think some links were posted by me and others end March/Early April re FDA willingness to accept other endpoints and about using MRI (backed up by the recent paper suggesting it is a more useful measure than subjective tests like 6MWT.

[hugus maximus] 21/4/2018 12:09

See Chris's link to Richard Pye Proactive interview above: He directly refers to the "option" of a push for FDA approval if 48 wk results continue as assumed. No safety issues and very much more forensic testing achievable with MRI rather than the various walk tests ... nothing to lose.

I've also observed more interest on NASDAQ forums in the USA over the past few weeks ... perhaps recent data and promise of positive 48 wk results are getting through.

Gold stars of merit for all prefects this term!

[wildbunch] 21/4/2018 10:18

Waterloo-Thanks. let's hope!

[waterloo01] 21/4/2018 07:16

Wildbunch, that's what the company have been saying, so yes. If the data continues to show improvement in muscles via MRI, then I think they have a decent shot at it.

[wildbunch] 20/4/2018 22:00

Could it be with the new FDA approach to drugs aimed at high unmet need that Summit could make a submission for approval if the 48 week test results are stellar with no safety issues?

[beanol] 20/4/2018 21:41

Thanks Waterloo What positive, moving and share price productive stuff.

[waterloo01] 20/4/2018 19:29

The poster

[hugus maximus] 20/4/2018 12:02

RNS More 24 wk info ....."analyses showed a high correlation between reductions in developmental myosin, a biomarker of muscle damage which was measured by muscle biopsy, and reductions in muscle inflammation, which was measured by magnetic resonance, in patients after 24 weeks of ezutromid treatment. These findings underpin existing evidence that by modulating utrophin protein production, ezutromid is reducing the severity of DMD."

Edit : One imagines a steady increase in share price toward 48 wk result is now inevitable, as the more data becomes available, this study at 24 wks is looking very strong.

[chrisatrdg] 19/4/2018 18:40

Richard Pye today:
Summit Therapeutics completes dosing of ezutromid in PhaseOut DMD clinical trial:


XX proactive XX investors